$0.17
▲ +$0.01
(+4.29%)
Vol 3.3M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$12.2M
ROE
-366.6%
Margin
-1383.5%
D/E
536.51
Beta
-2.67
52W
$1–$21
Wall Street Consensus
6 analysts · Apr 20260
Strong Buy
0
Buy
3
Hold
1
Sell
2
Strong Sell
0.0%
Buy Rating
Price Chart
Similar Stocks
RNAC
Cartesian Therapeutics Inc
$187.5M
WHWK
Whitehawk Therapeutics Inc
$114.1M
NKTX
Nkarta Inc
$131.4M
ABOS
Acumen Pharmaceuticals Inc
$127.8M
VTVT
vTv Therapeutics Inc
$167.1M
IMUX
Immunic Inc
$64.2M
TNYA
Tenaya Therapeutics Inc
$154.0M
HRTX
Heron Therapeutics Inc
$238.4M
UNCY
Unicycive Therapeutics Inc
$124.0M
Earnings
Beat rate: 100.0%
Next Report
May 12, 2026
EPS Estimate: $-0.31
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.31 | — | — |
| Sep 2025 | $-1.47 | $-0.86 | +$0.61 |
| Jun 2025 | $-1.74 | $-1.71 | +$0.03 |
| Mar 2025 | $-2.07 | $-1.41 | +$0.66 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$8.9M | -$8.2M | -$8.9M | -$11.2M | -$7.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -366.6% | -366.6% | -366.6% | -366.6% | -366.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -1383.5% | -1383.5% | -1383.5% | -1383.5% | -1383.5% |
| Gross Margin | — | 31.0% | 31.0% | 31.0% | 31.0% | 31.0% |
| D/E Ratio | — | 536.51 | 536.51 | 536.51 | 536.51 | 536.51 |
| Current Ratio | — | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 |
Key Ratios
ROA (TTM)
-64.9%
P/S (TTM)
2.12
P/B
3.4
EPS (TTM)
$-5.94
CF/Share
$-21.40
52W High
$20.60
52W Low
$0.51
$0.51
52-Week Range
$20.60
Financial Health
Free Cash Flow
-$10.9M
Net Debt
$8.8M
Cash
$21.1M
Total Debt
$29.9M
As of Sep 30, 2025
How does KALA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
KALA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.1
▼
84%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
3.4
▲
39%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
KALA profitability vs Biotechnology peers
ROE
-366.6%
▼
445%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-1383.5%
▼
382%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
31.0%
▼
61%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-64.9%
▼
39%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
KALA financial health vs Biotechnology peers
D/E ratio
536.5
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.0
▼
55%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
-2.7
▼
376%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
KALA fundamentals radar
KALA
Peer median
Industry
KALA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio